Rheumatoid Arthritis Drugs Market size is expected to grow significantly from 2019 to 2025.
Rheumatoid arthritis is an inflammatory disease that leads to pain and swelling in and around the joints. It generally affects hands and feet but can affect any joint in the body. Rheumatoid arthritis is an autoimmune condition caused due to the immune cells targeting own healthy body tissues. Patients experience joint swelling, stiffness and pain due to destruction of cartilage tissues and bones. The exact cause of disease is still unknown. Rheumatoid arthritis has four stages of progression and stage 3 represents the severe form of the disease. There are wide range of treatment available in the industry for rheumatoid arthritis and the choice of therapy depends on the stage and severity of the disease.
Development of biologics for an effective treatment of rheumatoid arthritis will render significant positive impact on rheumatoid arthritis drugs market growth. Decades of research has improved the understanding of pathogenesis of rheumatoid arthritis. This has helped in development of biologic agents that targets cellular interaction and targeted inflammatory cells. Infliximab, adalimumab, Anakinra are some of the biologics that are used for the treatment of rheumatoid arthritis. Furthermore, several drugs are in the stage of clinical development.
Growing prevalence of rheumatoid arthritis in the developing region will fuel the demand for antirheumatic drugs over the forecast period. The rheumatoid arthritis prevalence has increased drastically over the past few decades, especially in high income countries and trend is likely to remain so over the forecast timeframe. Women are found to be more vulnerable to the disease as compared to men. With the rising prevalence of the disease, people are increasingly becoming aware regarding the benefits of early diagnosis and timely treatment.
Global Rheumatoid Arthritis Drugs Market, By Route Of Administration, 2018 (USD Million)
Get more details on this report - Request Free Sample PDF
Based on drug class, the rheumatoid arthritis drugs market is segmented into biologic agents, corticosteroids, disease modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drug, others. Disease modifying antirheumatic drugs accounted for significant revenue share in 2018. Hydroxychloroquine, methotrexate, leflunomide and sulfasalazine are some of the commonly used traditional DMARDs. However, risks associated with use of these drugs and advent of newer DMARDs such as biologics will hamper the segment growth.
Based on route of administration, rheumatoid arthritis drugs market is segmented into oral and parenteral segments. Parenteral segment is projected to witness robust growth over the analysis timeframe. Bioavailability of drugs are significantly higher in parenteral form compared to oral dosage form. For instance, parenteral methotrexate was found to be more effective and indicated no additional adverse effects compared to oral methotrexate. However, cost and complexity associated with the administration is drastically higher in parenteral route of administration.
Based on distribution channels, rheumatoid arthritis drugs market is segmented into hospitals, retail pharmacies and online platforms. Online platforms will witness lucrative growth over the forecast timeframe due to increasing internet penetration and growing digital literacy rates in developing regions. Moreover, ease of usage and heavy discounts offered by online sellers on antirheumatic drugs will augment the segment growth.
North America rheumatoid arthritis drugs market dominated the industry in 2018 and the scenario is likely to remain so over the foreseeable future. High and rising prevalence of rheumatoid arthritis and robust research and development activities focused towards developing treatment of rheumatoid arthritis will drive the market. Moreover, high disposable income and well established presence of leading industry players will augment the market demand.
Prominent industry players operating in rheumatoid arthritis drugs market include AbbVie Inc., Amgen, Bristol-Myers Squibb Company, Genentech, Janssen Biotech, Sobi, and UCB. These market players putting enormous efforts in research and development activities to develop better therapeutic treatment for rheumatoid arthritis. For instance, in august 2019, U.S. food and drug administration approved AbbVie’s newly developed drug Rinvoq for treatment of rheumatoid arthritis. The newly approved drugs extended companies offerings in rheumatoid arthritis drugs market.
Rheumatoid Arthritis Drugs Market, By Drug Class, 2014-2025 (USD Million)
Rheumatoid Arthritis Drugs Market, By distribution channel, 2014-2025 (USD Million)
Rheumatoid Arthritis Drugs Market, By Route Of Administration, 2014-2025 (USD Million)
The above information is provided for the following regions and countries: